Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewAIDS/HIVInfectious disease Open Access | 10.1172/jci.insight.189909

CD8 T cells cross-restricted by HLA-B*57 and HLA-E*01 recognize HIV Gag with different functional profiles

Kevin J. Maroney,1 Michael A. Rose,1 Allisa K. Oman,1 Abha Chopra,2 Hua-Shiuan Hsieh,3 Zerufael Derza,3 Rachel Waterworth,3 Mark A. Brockman,3 Spyros A. Kalams,4 Anju Bansal,1 and Paul A. Goepfert1

1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia

3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America

Find articles by Maroney, K. in: PubMed | Google Scholar

1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia

3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America

Find articles by Rose, M. in: PubMed | Google Scholar

1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia

3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America

Find articles by Oman, A. in: PubMed | Google Scholar

1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia

3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America

Find articles by Chopra, A. in: PubMed | Google Scholar |

1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia

3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America

Find articles by Hsieh, H. in: PubMed | Google Scholar

1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia

3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America

Find articles by Derza, Z. in: PubMed | Google Scholar

1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia

3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America

Find articles by Waterworth, R. in: PubMed | Google Scholar

1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia

3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America

Find articles by Brockman, M. in: PubMed | Google Scholar |

1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia

3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America

Find articles by Kalams, S. in: PubMed | Google Scholar |

1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia

3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America

Find articles by Bansal, A. in: PubMed | Google Scholar |

1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia

3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America

Find articles by Goepfert, P. in: PubMed | Google Scholar |

Published December 18, 2025 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.189909.
Copyright © 2025, Maroney et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published December 18, 2025 - Version history
View PDF
Abstract

Few HIV-specific epitopes restricted by non-classical HLA-E have been described, and even less is known about the functional profile of responding CD8 T cells (CD8s). This study evaluates the functional characteristics of CD8s targeting the Gag epitope KF11 (KAFSPEVIPMF) restricted by either HLA-E (E-CD8s) or HLA-B57 (B57-CD8s). CD8s from eight people with HIV (PWH) were cocultured with KF11 peptide presented by cell lines expressing HLA-B*57:01, HLA-E*01:01 or E*01:03. CD8 responses were analyzed using scRNA-seq and scTCR-seq. Supernatants were also assessed for soluble protein profiling. HLA-I multimers were developed to identify CD8s restricted by HLA-B57 and/or HLA-E ex vivo. B57-CD8s secreted higher levels of cytotoxic cytokines such as IFNγ, whereas E-CD8s produced more chemotactic cytokines, including RANTES, CXCL10 (IP-10), and IL27, findings which were corroborated through scRNA sequencing. TCR clonotypes stimulated by KF11 were cross-restricted by HLA-B*57 and HLA-E*01/03 as demonstrated by in vitro T cell reporter assays and ex vivo multimer screening. Ex vivo CD8s were singly restricted by HLA-B57 and HLA-E, with dual restriction only observed in PWH with lower viral load. These findings demonstrate that certain HIV-specific CD8s in PWH exhibit dual restriction by HLA-B*57 and HLA-E*01/03, leading to functionally distinct immune responses depending upon the restricting allele(s).

Graphical Abstract
graphical abstract
Supplemental material

View

Version history
  • Version 1 (December 18, 2025): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts